Ane L Appelt1, Ivan R Vogelius2, John Pløen3, Søren R Rafaelsen3, Jan Lindebjerg3, Birgitte M Havelund3, Søren M Bentzen4, Anders Jakobsen5. 1. Department of Oncology, Vejle Hospital, Vejle, Denmark; Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark. Electronic address: ane.lindegaard.appelt@rsyd.dk. 2. Department of Radiation Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 3. Danish Colorectal Cancer Group South, Vejle Hospital, Vejle, Denmark. 4. Division of Biostatistics and Bioinformatics, University of Maryland Greenebaum Cancer Center, and Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland. 5. Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark; Danish Colorectal Cancer Group South, Vejle Hospital, Vejle, Denmark.
Abstract
PURPOSE/OBJECTIVE(S): Mature data on tumor control and survival are presented from a randomized trial of the addition of a brachytherapy boost to long-course neoadjuvant chemoradiation therapy (CRT) for locally advanced rectal cancer. METHODS AND MATERIALS: Between March 2005 and November 2008, 248 patients with T3-4N0-2M0 rectal cancer were prospectively randomized to either long-course preoperative CRT (50.4 Gy in 28 fractions, per oral tegafur-uracil and L-leucovorin) alone or the same CRT schedule plus a brachytherapy boost (10 Gy in 2 fractions). The primary trial endpoint was pathologic complete response (pCR) at the time of surgery; secondary endpoints included overall survival (OS), progression-free survival (PFS), and freedom from locoregional failure. RESULTS: Results for the primary endpoint have previously been reported. This analysis presents survival data for the 224 patients in the Danish part of the trial. In all, 221 patients (111 control arm, 110 brachytherapy boost arm) had data available for analysis, with a median follow-up time of 5.4 years. Despite a significant increase in tumor response at the time of surgery, no differences in 5-year OS (70.6% vs 63.6%, hazard ratio [HR] = 1.24, P=.34) and PFS (63.9% vs 52.0%, HR=1.22, P=.32) were observed. Freedom from locoregional failure at 5 years were 93.9% and 85.7% (HR=2.60, P=.06) in the standard and in the brachytherapy arms, respectively. There was no difference in the prevalence of stoma. Explorative analysis based on stratification for tumor regression grade and resection margin status indicated the presence of response migration. CONCLUSIONS: Despite increased pathologic tumor regression at the time of surgery, we observed no benefit on late outcome. Improved tumor regression does not necessarily lead to a relevant clinical benefit when the neoadjuvant treatment is followed by high-quality surgery.
RCT Entities:
PURPOSE/OBJECTIVE(S): Mature data on tumor control and survival are presented from a randomized trial of the addition of a brachytherapy boost to long-course neoadjuvant chemoradiation therapy (CRT) for locally advanced rectal cancer. METHODS AND MATERIALS: Between March 2005 and November 2008, 248 patients with T3-4N0-2M0 rectal cancer were prospectively randomized to either long-course preoperative CRT (50.4 Gy in 28 fractions, per oral tegafur-uracil and L-leucovorin) alone or the same CRT schedule plus a brachytherapy boost (10 Gy in 2 fractions). The primary trial endpoint was pathologic complete response (pCR) at the time of surgery; secondary endpoints included overall survival (OS), progression-free survival (PFS), and freedom from locoregional failure. RESULTS: Results for the primary endpoint have previously been reported. This analysis presents survival data for the 224 patients in the Danish part of the trial. In all, 221 patients (111 control arm, 110 brachytherapy boost arm) had data available for analysis, with a median follow-up time of 5.4 years. Despite a significant increase in tumor response at the time of surgery, no differences in 5-year OS (70.6% vs 63.6%, hazard ratio [HR] = 1.24, P=.34) and PFS (63.9% vs 52.0%, HR=1.22, P=.32) were observed. Freedom from locoregional failure at 5 years were 93.9% and 85.7% (HR=2.60, P=.06) in the standard and in the brachytherapy arms, respectively. There was no difference in the prevalence of stoma. Explorative analysis based on stratification for tumor regression grade and resection margin status indicated the presence of response migration. CONCLUSIONS: Despite increased pathologic tumor regression at the time of surgery, we observed no benefit on late outcome. Improved tumor regression does not necessarily lead to a relevant clinical benefit when the neoadjuvant treatment is followed by high-quality surgery.
Authors: Anders Jakobsen; John Ploen; Té Vuong; Ane Appelt; Jan Lindebjerg; Soren R Rafaelsen Journal: Int J Radiat Oncol Biol Phys Date: 2012-05-15 Impact factor: 7.038
Authors: F Bonnetain; J F Bosset; J P Gerard; G Calais; T Conroy; L Mineur; O Bouché; P Maingon; O Chapet; L Radosevic-Jelic; N Methy; L Collette Journal: Eur J Cancer Date: 2012-04-14 Impact factor: 9.162
Authors: Ane L Appelt; John Pløen; Ivan R Vogelius; Søren M Bentzen; Anders Jakobsen Journal: Int J Radiat Oncol Biol Phys Date: 2012-07-03 Impact factor: 7.038
Authors: Stuart J Wong; Kathryn Winter; Neal J Meropol; Pramila Rani Anne; Lisa Kachnic; Asif Rashid; James C Watson; Edith Mitchell; Jondavid Pollock; Robert Jeffrey Lee; Michael Haddock; Beth A Erickson; Christopher G Willett Journal: Int J Radiat Oncol Biol Phys Date: 2011-07-19 Impact factor: 7.038
Authors: Samuel Y Ngan; Bryan Burmeister; Richard J Fisher; Michael Solomon; David Goldstein; David Joseph; Stephen P Ackland; David Schache; Bev McClure; Sue-Anne McLachlan; Joseph McKendrick; Trevor Leong; Cris Hartopeanu; John Zalcberg; John Mackay Journal: J Clin Oncol Date: 2012-09-24 Impact factor: 44.544
Authors: Hsiang-Chi Kuo; Keyur J Mehta; Ravindra Yaparpalvi; Alan Lee; Dinesh Mynampati; William Bodner; Madhur Garg; David Huang; Wolfgang A Tomé; Shalom Kalnicki Journal: Technol Cancer Res Treat Date: 2017-05-08